Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 12/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17939337 | 0.82 | NTRK1 (0.46) | NTRK1MAPK1SLC2A1PIK3CAPIK3CG | |
| SCHEMBL17939340 | 0.82 | NTRK1 (0.46) | NTRK1MAPK1SLC2A1PIK3CAPIK3CG | |
| SCHEMBL17951910 | 0.80 | NTRK1 (0.47) | NTRK1MAPK1SLC2A1PIK3CAPIK3CG | |
| SCHEMBL17939097 | 0.80 | JAK3 (0.50) | NTRK1MAPK1 | |
| SCHEMBL17939488 | 0.80 | JAK3 (0.50) | NTRK1MAPK1 | |
| SCHEMBL17939098 | 0.80 | JAK3 (0.50) | NTRK1MAPK1 | |
| SCHEMBL19068203 | 0.76 | NTRK1 (0.54) | NTRK1MAPK1SLC2A1PIK3CAPIK3CG | |
| SCHEMBL17939062 | 0.76 | JAK3 (0.45) | NTRK1MAPK1 | |
| SCHEMBL19068207 | 0.75 | NTRK1 (0.53) | NTRK1MAPK1SLC2A1PIK3CAPIK3CG | |
| SCHEMBL17939583 | 0.75 | JAK3 (0.46) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190106439-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | CONFLUENCE LIFE SCIENCES, INC. | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106439-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, NFKBIA, TNNI3K | NTRK1 2003/4885MAPK1 609/4885SLC2A1 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.